There is a great need for new therapies for carcinomas that have progressed on or not
responded to current therapy. There are no approved Met targeted agents in standard clinical
use. In the population of subjects with advanced carcinomas that are unresponsive to standard
of care, and based on the relatively safe, reversible and monitorable toxicity profile of
ASLAN002 in non clinical studies, the potential for benefit from ASLAN002 outweighs the
potential risks for toxicity.
The purpose of this study is to identify the maximum tolerated dose of ASLAN002 in subjects
with advanced or metastatic solid tumours, as well as to define the overall safety profile of